Report Summary
Personalized medicine is at an early stage of development. Scientists found that some cancer cells have particular proteins in the cell and others don’t. Sometimes, cancer cells have far more of a particular protein than healthy cells. Genetic testing of cancer cells and normal cells helps doctors customize treatment to individual patient needs. Personalized treatments may cause fewer side effects than standard options. Some people are already benefiting from this approach.
In 2020, the global Personalized Cancer Medicine market size was xx million US$ and it is expected to reach xx million US$ by the end of 2027, with a CAGR of xx% during 2021-2027.
This report focuses on the global Personalized Cancer Medicine status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Personalized Cancer Medicine development in United States, Europe and China.
The key players covered in this study
Abbott
Merck
Novartis
Amgen
Celgene
Bayer
Roche
Astellas
Astrazeneca
Johnson & Johnson
Agilent
Takeda
Market segment by Type, the product can be split into
Monoclonal Antibodies
Personalized Cancer Vaccines
Other
Market segment by Application, split into
Breast Cancer
Lung Cancer
Chronic Myeloid Leukaemia
Bowel Cancer
Other Cancer
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Personalized Cancer Medicine status, future forecast, growth opportunity, key market and key players.
To present the Personalized Cancer Medicine development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Personalized Cancer Medicine are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table Of Contents
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Personalized Cancer Medicine Market Size Growth Rate by Type (2017-2027)
1.4.2 Monoclonal Antibodies
1.4.3 Personalized Cancer Vaccines
1.4.4 Other
1.5 Market by Application
1.5.1 Global Personalized Cancer Medicine Market Share by Application (2017-2027)
1.5.2 Breast Cancer
1.5.3 Lung Cancer
1.5.4 Chronic Myeloid Leukaemia
1.5.5 Bowel Cancer
1.5.6 Other Cancer
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Personalized Cancer Medicine Market Size
2.2 Personalized Cancer Medicine Growth Trends by Regions
2.2.1 Personalized Cancer Medicine Market Size by Regions (2017-2027)
2.2.2 Personalized Cancer Medicine Market Share by Regions (2017-2020)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Personalized Cancer Medicine Market Size by Manufacturers
3.1.1 Global Personalized Cancer Medicine Revenue by Manufacturers (2017-2020)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Manufacturers (2017-2020)
3.1.3 Global Personalized Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.2 Personalized Cancer Medicine Key Players Head office and Area Served
3.3 Key Players Personalized Cancer Medicine Product/Solution/Service
3.4 Date of Enter into Personalized Cancer Medicine Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Personalized Cancer Medicine Market Size by Type (2017-2020)
4.2 Global Personalized Cancer Medicine Market Size by Application (2017-2020)
5 United States
5.1 United States Personalized Cancer Medicine Market Size (2017-2020)
5.2 Personalized Cancer Medicine Key Players in United States
5.3 United States Personalized Cancer Medicine Market Size by Type
5.4 United States Personalized Cancer Medicine Market Size by Application
6 Europe
6.1 Europe Personalized Cancer Medicine Market Size (2017-2020)
6.2 Personalized Cancer Medicine Key Players in Europe
6.3 Europe Personalized Cancer Medicine Market Size by Type
6.4 Europe Personalized Cancer Medicine Market Size by Application
7 China
7.1 China Personalized Cancer Medicine Market Size (2017-2020)
7.2 Personalized Cancer Medicine Key Players in China
7.3 China Personalized Cancer Medicine Market Size by Type
7.4 China Personalized Cancer Medicine Market Size by Application
8 Japan
8.1 Japan Personalized Cancer Medicine Market Size (2017-2020)
8.2 Personalized Cancer Medicine Key Players in Japan
8.3 Japan Personalized Cancer Medicine Market Size by Type
8.4 Japan Personalized Cancer Medicine Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Personalized Cancer Medicine Market Size (2017-2020)
9.2 Personalized Cancer Medicine Key Players in Southeast Asia
9.3 Southeast Asia Personalized Cancer Medicine Market Size by Type
9.4 Southeast Asia Personalized Cancer Medicine Market Size by Application
10 India
10.1 India Personalized Cancer Medicine Market Size (2017-2020)
10.2 Personalized Cancer Medicine Key Players in India
10.3 India Personalized Cancer Medicine Market Size by Type
10.4 India Personalized Cancer Medicine Market Size by Application
11 Central & South America
11.1 Central & South America Personalized Cancer Medicine Market Size (2017-2020)
11.2 Personalized Cancer Medicine Key Players in Central & South America
11.3 Central & South America Personalized Cancer Medicine Market Size by Type
11.4 Central & South America Personalized Cancer Medicine Market Size by Application
12 International Players Profiles
12.1 Abbott
12.1.1 Abbott Company Details
12.1.2 Company Description and Business Overview
12.1.3 Personalized Cancer Medicine Introduction
12.1.4 Abbott Revenue in Personalized Cancer Medicine Business (2017-2020)
12.1.5 Abbott Recent Development
12.2 Merck
12.2.1 Merck Company Details
12.2.2 Company Description and Business Overview
12.2.3 Personalized Cancer Medicine Introduction
12.2.4 Merck Revenue in Personalized Cancer Medicine Business (2017-2020)
12.2.5 Merck Recent Development
12.3 Novartis
12.3.1 Novartis Company Details
12.3.2 Company Description and Business Overview
12.3.3 Personalized Cancer Medicine Introduction
12.3.4 Novartis Revenue in Personalized Cancer Medicine Business (2017-2020)
12.3.5 Novartis Recent Development
12.4 Amgen
12.4.1 Amgen Company Details
12.4.2 Company Description and Business Overview
12.4.3 Personalized Cancer Medicine Introduction
12.4.4 Amgen Revenue in Personalized Cancer Medicine Business (2017-2020)
12.4.5 Amgen Recent Development
12.5 Celgene
12.5.1 Celgene Company Details
12.5.2 Company Description and Business Overview
12.5.3 Personalized Cancer Medicine Introduction
12.5.4 Celgene Revenue in Personalized Cancer Medicine Business (2017-2020)
12.5.5 Celgene Recent Development
12.6 Bayer
12.6.1 Bayer Company Details
12.6.2 Company Description and Business Overview
12.6.3 Personalized Cancer Medicine Introduction
12.6.4 Bayer Revenue in Personalized Cancer Medicine Business (2017-2020)
12.6.5 Bayer Recent Development
12.7 Roche
12.7.1 Roche Company Details
12.7.2 Company Description and Business Overview
12.7.3 Personalized Cancer Medicine Introduction
12.7.4 Roche Revenue in Personalized Cancer Medicine Business (2017-2020)
12.7.5 Roche Recent Development
12.8 Astellas
12.8.1 Astellas Company Details
12.8.2 Company Description and Business Overview
12.8.3 Personalized Cancer Medicine Introduction
12.8.4 Astellas Revenue in Personalized Cancer Medicine Business (2017-2020)
12.8.5 Astellas Recent Development
12.9 Astrazeneca
12.9.1 Astrazeneca Company Details
12.9.2 Company Description and Business Overview
12.9.3 Personalized Cancer Medicine Introduction
12.9.4 Astrazeneca Revenue in Personalized Cancer Medicine Business (2017-2020)
12.9.5 Astrazeneca Recent Development
12.10 Johnson & Johnson
12.10.1 Johnson & Johnson Company Details
12.10.2 Company Description and Business Overview
12.10.3 Personalized Cancer Medicine Introduction
12.10.4 Johnson & Johnson Revenue in Personalized Cancer Medicine Business (2017-2020)
12.10.5 Johnson & Johnson Recent Development
12.11 Agilent
12.12 Takeda
13 Market Forecast 2021-2027
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2021-2027)
13.10 Market Size Forecast by Application (2021-2027)
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
